Cost Analysis of the Treatment of Schizophrenia in the UK

Stephen Almond and Owen O’Donnell
Authors registered in the RePEc Author Service: Owen O'Donnell

PharmacoEconomics, 2000, vol. 17, issue 4, 383-389

Abstract: Objective: To compare the costs of 2 atypical drug therapies (olanzapine and risperidone)with one another and with a conventional antipsychotic (haloperidol) in the treatment of schizophrenia. Design and setting: The analysis is based on a simulation model with parameter values taken mainly from clinical trial data in patients with schizophrenia, and was conducted within a UK context. Results: The 3 therapies are approximately cost neutral over a 5-year period (olanzapine £35 701, risperidone £36 590 and haloperidol £36 653). There is evidence of greater efficacy with the atypical drugs [average percentage of 5 years with Brief Psychiatric Rating Scale (BPRS) scores >18: olanzapine 63.6%, risperidone 63.0% and haloperidol 52.2%]. The cost and efficacy differences between the 2 atypical drugs are too small to rank them in terms of cost effectiveness. Extensive sensitivity analysis does not change any of the main conclusions. Conclusions: Given evidence of efficacy gains to the atypical drugs, these represent cost-effective treatment options. Prospective data from nontrial treatment settings would help substantiate the model findings. Copyright Adis International Limited 2000

Date: 2000
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2165/00019053-200017040-00008 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:17:y:2000:i:4:p:383-389

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/00019053-200017040-00008

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().